Skip to main content
Kukje Pharma Co., Ltd. logo

Kukje Pharma Co., Ltd. — Investor Relations & Filings

Ticker · 002720 ISIN · KR7002720001 KO Manufacturing
Open in API
Filings indexed 297 across all filing types
Latest filing 2024-03-08 Major Shareholding Noti…
Country KR South Korea
Listing KO 002720

About Kukje Pharma Co., Ltd.

https://www.kukjepharm.co.kr/index.php?…

Kukje Pharma Co., Ltd. is a company engaged in the manufacturing, distribution, import, and export of pharmaceutical products, cosmetics, and health supplements. Its core offerings include a wide range of prescription (ETC) and over-the-counter (OTC) drugs, with a notable specialization in antibiotics such as Cephalosporins. In addition to its primary pharmaceutical business, the company also develops and markets cosmetic products, food supplements, and respiratory protection face masks. The company serves both domestic and international markets.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding of Stocks, etc.), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the shareholding status, changes in ownership, and collateral agreements of major shareholders (including special related parties) of Kukje Pharmaceutical Co., Ltd. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2024-03-08 Korean
주주총회소집결의
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal notice of an upcoming Annual General Meeting (AGM) for Kukje Pharma, detailing the date, location, agenda items (such as financial statement approval, director appointments, and auditor selection), and voting procedures. This document serves as the official proxy solicitation and information statement provided to shareholders to inform them of the meeting and request their participation/votes. Therefore, it is classified as a Proxy Solicitation & Information Statement (PSI).
2024-03-06 Korean
주주총회집중일개최사유신고
AGM Information Classification · 98% confidence The document is a regulatory filing submitted to the Korea Exchange (KRX) regarding the scheduling of a General Meeting of Shareholders on a 'concentrated date'. It explains the company's inability to avoid the concentrated date due to financial reporting schedules. As this is a regulatory disclosure regarding meeting logistics and compliance with the Korea Listed Companies Association's guidelines, and does not fit into specific categories like AGM-R (presentation materials) or PSI (proxy solicitation), it is best classified as a general regulatory filing.
2024-03-06 Korean
주주총회소집공고
AGM Information Classification · 98% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for Kukje Pharm. It contains the agenda for the upcoming Annual General Meeting (AGM), including reports on financial statements, director appointments, and governance matters. While it contains financial data, it is primarily a solicitation and notification document for shareholders to attend the meeting and vote, which falls under the Proxy Solicitation & Information Statement category.
2024-03-06 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy), which is a standard regulatory filing in South Korea (often referred to as a Proxy Statement). It provides shareholders with information regarding the upcoming Annual General Meeting (AGM), including agenda items, voting procedures, and financial summaries to assist in the proxy solicitation process. This fits the definition of a Proxy Solicitation & Information Statement (PSI).
2024-03-06 Korean
매출액또는손익구조30%(대규모법인은15%)이상변경
Earnings Release Classification · 100% confidence The document is a regulatory filing from a Korean company (Kukje Pharma) announcing a significant change in financial structure (revenue/profit/loss) exceeding 30%. It provides preliminary financial data, including revenue, operating profit, and net income, and explicitly states that these figures are subject to change following an external audit. This type of disclosure is a standard regulatory requirement for listed companies in Korea to report material financial changes before the final audit report is published. It fits the 'Earnings Release' (ER) category as it provides the initial announcement of financial results and key highlights. FY 2023
2024-02-02 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.